INDV Indivior PLC Ordinary Shares

$24.32

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Indivior PLC Ordinary Shares

Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.

Website: https://www.indivior.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1625297
Address
10710 MIDLOTHIAN TURNPIKE, SUITE 125, NORTH CHESTERFIELD, VA, GB
Valuation
Market Cap
$1.14B
P/E Ratio
450.50
PEG Ratio
nan
Price to Book
145.25
Performance
EPS
$0.02
Dividend Yield
—
Profit Margin
-4.04%
ROE
12.20%
Technicals
50D MA
$9.55
200D MA
$10.72
52W High
$19.13
52W Low
$7.33
Fundamentals
Shares Outstanding
125M
Target Price
$15.67
Beta
0.32

INDV EPS Estimates vs Actual

● Estimated
● Actual

INDV News & Sentiment

Aug 13, 2025 • Motley Fool NEUTRAL
Durect Posts Narrower Loss in Fiscal Q2
Durect ( NASDAQ:DRRX ) , a biopharmaceutical company focused on liver disease therapeutics, released results for the second quarter of fiscal 2025 on August 12, 2025. Durect posted better-than-expected earnings per share ( GAAP ) of $ ( 0.07 ) , surpassing analyst forecasts of $ ( 0.13 ) ( GAAP ) ...
Aug 06, 2025 • Benzinga SOMEWHAT-BULLISH
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Almonty Indus ( NASDAQ:ALM ) , Adagene ( NASDAQ:ADAG )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Aug 05, 2025 • Zacks Commentary SOMEWHAT-BULLISH
All You Need to Know About Indivior ( INDV ) Rating Upgrade to Strong Buy
Indivior (INDV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aug 05, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Best Momentum Stock to Buy for August 5th
FFIV, INDV and NVT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 5, 2025.
Aug 05, 2025 • Zacks Commentary SOMEWHAT-BULLISH
New Strong Buy Stocks for August 5th
ARMN, QUAD, NVST, INDV and BJRI have been added to the Zacks Rank #1 (Strong Buy) List on August 5, 2025.
Aug 01, 2025 • Motley Fool SOMEWHAT-BULLISH
Indivior ( INDV ) Q2 EPS Jumps 104%
Indivior ( NASDAQ:INDV ) , a global pharmaceutical company known for its treatments for opioid use disorder ( OUD ) , reported results on July 31, 2025. The main news was a sharp outperformance compared to analyst estimates, with non-GAAP EPS of $0.51 beating the $0.25 consensus.
Sentiment Snapshot

Average Sentiment Score:

0.046
50 articles with scored sentiment

Overall Sentiment:

Neutral

INDV Reported Earnings

Feb 20, 2025
Dec 31, 2024 (Pre market)
0.06 Surprise
  • Reported EPS: $0.32
  • Estimate: $0.26
  • Whisper: —
  • Surprise %: 22.6%
Oct 24, 2024
Sep 30, 2024 (Pre market)
-0.28 Surprise
  • Reported EPS: $0.03
  • Estimate: $0.31
  • Whisper: —
  • Surprise %: -90.3%
Jul 25, 2024
Jun 30, 2024 (Pre market)
-1.19 Surprise
  • Reported EPS: $-0.79
  • Estimate: $0.40
  • Whisper: —
  • Surprise %: -297.5%
Apr 25, 2024
Mar 31, 2024 (Post market)
-0.05 Surprise
  • Reported EPS: $0.37
  • Estimate: $0.42
  • Whisper: —
  • Surprise %: -11.9%
Feb 22, 2024
Dec 31, 2023 (Pre market)
0.15 Surprise
  • Reported EPS: $0.43
  • Estimate: $0.28
  • Whisper: —
  • Surprise %: 53.6%
Nov 09, 2023
Sep 30, 2023 (Pre market)
-1.28 Surprise
  • Reported EPS: $-0.98
  • Estimate: $0.30
  • Whisper: —
  • Surprise %: -426.7%
Jul 27, 2023
Jun 30, 2023 (Pre market)
0.17 Surprise
  • Reported EPS: $0.39
  • Estimate: $0.22
  • Whisper: —
  • Surprise %: 77.3%
Apr 27, 2023
Mar 31, 2023 (Pre market)
0.0 Surprise
  • Reported EPS: $0.40
  • Estimate: $0.40
  • Whisper: —
  • Surprise %: 0.0%
Feb 16, 2023
Dec 31, 2022 (Pre market)
-1.61 Surprise
  • Reported EPS: $-1.34
  • Estimate: $0.27
  • Whisper: —
  • Surprise %: -596.6%

Financials